Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome

(E-pub Ahead of Print)

Author(s): Nasrin Aktar, Ahmed Moudud, Tingting Chen, Xiaoqing Gao, Hanhui Min, Meng Tang, Xiaohui Zhou*

Journal Name: Current Pharmaceutical Design

Become EABM
Become Reviewer
Call for Editor


Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative void-ing, sexual dysfunction and pelvic pain. Chronic prostatitis/chronic pelvic pain syn-drome weakens the quality of life and poses adverse psychological effects on the pa-tients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phos-phodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal anti-body, anticholinergics, gabapentin, pregabalin are used clinically. These therapies em-phasise on easing the symptoms in specific areas without curing the fundamental cause where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective to treat this condition.

Keywords: Chronic prostatitis, chronic pelvic pain syndrome, irritative voiding, sexual dysfunc-tion, pelvic pain, pharmacological interventions

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1381612827666210322125054
Price: $95

Article Metrics

PDF: 33